CY1109300T1 - Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων - Google Patents

Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων

Info

Publication number
CY1109300T1
CY1109300T1 CY20091100845T CY091100845T CY1109300T1 CY 1109300 T1 CY1109300 T1 CY 1109300T1 CY 20091100845 T CY20091100845 T CY 20091100845T CY 091100845 T CY091100845 T CY 091100845T CY 1109300 T1 CY1109300 T1 CY 1109300T1
Authority
CY
Cyprus
Prior art keywords
new
ordinated
heterocyclic rings
formula
prophylaxis
Prior art date
Application number
CY20091100845T
Other languages
English (en)
Inventor
Brian Aquila
Michael Howard Block
Audrey Davies
Jayachandran Ezhuthachan
Sandra Filla
Richard William Luke
Timothy Pontz
Maria-Elena Theoclitou
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0300627A external-priority patent/SE0300627D0/xx
Priority claimed from SE0301138A external-priority patent/SE0301138D0/xx
Priority claimed from SE0301697A external-priority patent/SE0301697D0/xx
Priority claimed from SE0302826A external-priority patent/SE0302826D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1109300T1 publication Critical patent/CY1109300T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Αυτή η εφεύρεση αναφέρεται σε νέες ενώσεις του τύπου (I) (εδώ θα πρέπει να εισαχθεί ένας χημικός τύπος - παρακαλώ ίδετε το εσωκλεισμένο στην παρούσα αντίγραφο) m = 0, 1, 2 n = 0, 1 (I) όπου τα R1, R2, R3, R4, R5, R6, R7, R8 και R9 είναι όπως ορίζονται στον προσδιορισμό και στις φαρμακευτικές τους συνθέσεις και στις μεθόδους χρήσης τους. Αυτές οι νέες ενώσεις παρέχουν μία θεραπεία ή προφύλαξη από τον καρκίνο.
CY20091100845T 2003-03-07 2009-08-10 Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων CY1109300T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0300627A SE0300627D0 (sv) 2003-03-07 2003-03-07 Novel fused heterocycles and uses therof
SE0301138A SE0301138D0 (sv) 2003-04-15 2003-04-15 Novel fused heterocycles and uses thereof
SE0301697A SE0301697D0 (sv) 2003-06-10 2003-06-10 Novel fused heterocycles and uses thereof
SE0302826A SE0302826D0 (sv) 2003-10-24 2003-10-24 Novel fused heterocycles and uses thereof
EP04717339A EP1601673B1 (en) 2003-03-07 2004-03-04 Fused heterocycles and uses thereof

Publications (1)

Publication Number Publication Date
CY1109300T1 true CY1109300T1 (el) 2014-07-02

Family

ID=32966643

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100845T CY1109300T1 (el) 2003-03-07 2009-08-10 Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων

Country Status (25)

Country Link
US (1) US20060270689A1 (el)
EP (1) EP1601673B1 (el)
JP (2) JP3947758B2 (el)
KR (1) KR20050107784A (el)
AR (1) AR043487A1 (el)
AT (1) ATE433448T1 (el)
AU (1) AU2004218080B2 (el)
BR (1) BRPI0408150A (el)
CA (1) CA2518224C (el)
CY (1) CY1109300T1 (el)
DE (1) DE602004021477D1 (el)
DK (1) DK1601673T3 (el)
ES (1) ES2326647T3 (el)
HK (1) HK1084390A1 (el)
IS (1) IS8036A (el)
MX (1) MXPA05009577A (el)
MY (1) MY141583A (el)
NO (1) NO20054340L (el)
NZ (1) NZ542227A (el)
PL (1) PL1601673T3 (el)
PT (1) PT1601673E (el)
SI (1) SI1601673T1 (el)
TW (1) TW200510427A (el)
UA (1) UA81470C2 (el)
WO (1) WO2004078758A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309892A2 (pt) 2002-05-09 2011-04-05 Cytokinetics Inc composto, composição, métodos para modular a atividade da cinesina de ksp, para inibir a ksp, e para o tratamento de uma doença proliferativa celular, e, uso de um composto
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
US20040242566A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
MX2007001954A (es) * 2004-08-18 2007-05-09 Astrazeneca Ab Heterociclicos fusionados seleccionados y sus usos.
UY29070A1 (es) * 2004-08-18 2006-03-31 Astrazeneca Ab Enantiómeros de heterocíclicos fusionados y sus usos
EP1856128A4 (en) * 2005-01-19 2009-12-23 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
DE102005027168A1 (de) 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
CN101842100A (zh) 2007-06-21 2010-09-22 诺伊罗纳森特公司 使用异噻唑并嘧啶酮刺激神经发生和抑制神经元变性的方法和组合物
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
CN114478429B (zh) * 2020-11-13 2023-11-17 中国科学院大连化学物理研究所 一种3-烷硫基异噻唑衍生物及其合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
MXPA03005152A (es) * 2000-12-11 2004-10-14 Tularik Inc Antogonista de cxcr3.
US6809102B2 (en) * 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US7060705B2 (en) * 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US7262187B2 (en) * 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
DE60222302T2 (de) * 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
JP2005515208A (ja) * 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
AU2002357043B2 (en) * 2001-12-06 2008-04-24 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7262186B2 (en) * 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor
RU2308454C9 (ru) * 2002-04-17 2008-05-10 Цитокинетикс, Инк. Соединения, композиции на их основе и способы их использования
BR0309892A2 (pt) * 2002-05-09 2011-04-05 Cytokinetics Inc composto, composição, métodos para modular a atividade da cinesina de ksp, para inibir a ksp, e para o tratamento de uma doença proliferativa celular, e, uso de um composto
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005536475A (ja) * 2002-05-23 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
DE60326248D1 (de) * 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
ATE458735T1 (de) * 2003-06-20 2010-03-15 Novartis Vaccines & Diagnostic Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs
EP1670456A2 (en) * 2003-10-06 2006-06-21 Cytokinetics, Inc. Compounds, compositions and methods
JP2007510660A (ja) * 2003-11-07 2007-04-26 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
EP1732926B1 (en) * 2004-04-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Mitotic kinesin inhibitors
JP2008517057A (ja) * 2004-10-19 2008-05-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インドールおよびベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
JP3947758B2 (ja) 2007-07-25
ES2326647T3 (es) 2009-10-16
NZ542227A (en) 2008-12-24
PT1601673E (pt) 2009-07-29
MY141583A (en) 2010-05-14
HK1084390A1 (en) 2006-07-28
CA2518224C (en) 2010-06-15
CA2518224A1 (en) 2004-09-16
TW200510427A (en) 2005-03-16
AU2004218080A1 (en) 2004-09-16
IS8036A (is) 2005-09-19
UA81470C2 (en) 2008-01-10
AU2004218080B2 (en) 2008-01-03
MXPA05009577A (es) 2005-12-12
ATE433448T1 (de) 2009-06-15
JP2007063257A (ja) 2007-03-15
EP1601673A1 (en) 2005-12-07
NO20054340L (no) 2005-09-26
SI1601673T1 (sl) 2009-10-31
BRPI0408150A (pt) 2006-03-21
PL1601673T3 (pl) 2009-10-30
DK1601673T3 (da) 2009-08-24
DE602004021477D1 (de) 2009-07-23
US20060270689A1 (en) 2006-11-30
AR043487A1 (es) 2005-08-03
KR20050107784A (ko) 2005-11-15
WO2004078758A1 (en) 2004-09-16
EP1601673B1 (en) 2009-06-10
JP2006519853A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
CY1109300T1 (el) Νεοι συντηγμενοι ετεροκυκλικοι δακτυλιοι και χρησεις αυτων
CY1108894T1 (el) Νεα παραγωγα βενζιμιδαζολης
SE0202133D0 (sv) Novel compounds
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
CY1107851T1 (el) Παραγωγα πυρολλο-πυριδινης και η χρηση τους ως ανταγωνιστων crth2
NO20064763L (no) Forbindelser og fremgangsmater for behandling av dyslipidemi
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
CY1110956T1 (el) Παραγωγα πυριδο-πυραζινης χρησιμα ως ζιζανιοκτονες ενωσεις
ATE433447T1 (de) Pyrimiidinverbindungen
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
CY1109227T1 (el) Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
CY1108254T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
CY1107196T1 (el) Υποκατεστημενα παραγωγα 2,4-διϋδρο-πυρρολο (3,4-β) -κινολιν-9-ονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
CY1105047T1 (el) Ενωσεις πυριδοπυριμιδινονης, η μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τις περιεχουν
CY1107149T1 (el) Νεα παραγωγα αμιδινοβενζυλαμινης και χρηση τους ως αναστολεων θρομβινης
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
CY1107485T1 (el) 3-θειομεθυλπυραζoλες ως παρασιτοκτoνα
NO20044526L (no) Hemisterlinderivater og anvendelser derav
SE0303541D0 (sv) New compounds
ATE482933T1 (de) Sulfopyrrolderivate
SE0303090D0 (sv) Novel compounds